Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis
about
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart AssociationUsing benefit-based tailored treatment to improve the use of antihypertensive medications.Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines.Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysisSupport of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines.Cost-utility of aspirin and proton pump inhibitors for primary preventionThe role of aspirin in women's healthAspirin for primary prevention of cardiovascular disease in diabetes mellitusQuantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey.Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis.The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population.SF-6D and EQ-5D result in widely divergent incremental cost-effectiveness ratios in a clinical trial of older women: implications for health policy decisions.Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysisCost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease.Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in menAspirin for primary prevention: do potential benefits outweigh the risks?Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients.Cost-effectiveness of oral antiplatelet agents--current and future perspectives.A systematic review on the application of cardiovascular risk prediction models in pharmacoeconomics, with a focus on primary prevention.Optimizing the use of aspirin for cardiovascular prevention.Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.Cost effectiveness and return on investment of a scalable community weight loss intervention.Dynamic treatment selection and modification for personalised blood pressure therapy using a Markov decision process model: a cost-effectiveness analysis.Cost-effectiveness of renin-guided treatment of hypertension.Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy.Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association.
P2860
Q27687851-F5563BF0-F3DD-4AE2-8B3F-00B257DD007EQ30501645-E7506E2F-39FB-494B-A177-9DBF6987226AQ33632026-FDFBD706-83FF-4771-8483-D488D3FF0A11Q33689688-A63173DD-0EF4-47A7-903C-4FC068069BD3Q33873025-33FA533F-4114-46EB-A20F-41A685211D45Q34143079-AC995275-EC8D-45CC-8679-C5AD859622DCQ34542774-533A6813-07F0-46F4-8ED3-67C21FD0E261Q35108108-41DD3B81-2570-4750-BA82-B64FDAF1A9DCQ35119642-7D05F8D2-EB00-4F5C-9598-B23A3A6EAFD3Q35132896-C4382583-BD2D-49FA-BD50-1C70D1BA2125Q35604901-2176160F-8AAA-4C62-A2CD-279285485AC1Q35694196-3677AB6F-B7AD-4574-AD1A-EB504842F208Q35753875-0235C639-E28B-4DC1-B62D-D258FC48280AQ35867796-BE21AC5C-50E9-42D1-91B3-3DACE9896D40Q36062323-8B9B6AA7-2B1D-4532-9AA0-AF1640D157A6Q36836401-5CC34DF5-C208-4408-982A-B4D8FE108EF4Q37231429-3589698C-C61B-4767-9885-CAA74346FCEDQ37542357-AAFC103D-B468-4288-97FE-ED44B70962F9Q37567490-48FF0CCB-7ADA-4A4F-8702-67942C0DF04FQ37597666-7845674B-32FC-4E56-A918-1F8F5FB68735Q37913974-72EF38A6-AD90-477E-9ED0-42921FA9DB85Q38044398-75177F55-2449-4438-8C17-5AFBD8A0D599Q38107179-3A2DB4CF-2F66-4D73-B644-7E8C677FA6F3Q39091796-5ED6A772-DA1D-41C5-BE46-39251AE0728CQ45069487-035E1546-E5E1-48DA-A0D4-98A79F79977EQ45982769-874A42E3-B7DE-41F0-A02A-F58720C9E184Q46588945-85D41BED-4485-48D7-8EE7-792DAC08D52CQ50460101-387470FB-9F8B-4651-9825-175D38439BE5Q55053962-8809EAD3-40C8-4318-8B9D-7D6DB4C3521A
P2860
Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Aspirin for the primary preven ...... women: a cost-utility analysis
@ast
Aspirin for the primary preven ...... women: a cost-utility analysis
@en
Aspirin for the primary preven ...... women: a cost-utility analysis
@nl
type
label
Aspirin for the primary preven ...... women: a cost-utility analysis
@ast
Aspirin for the primary preven ...... women: a cost-utility analysis
@en
Aspirin for the primary preven ...... women: a cost-utility analysis
@nl
prefLabel
Aspirin for the primary preven ...... women: a cost-utility analysis
@ast
Aspirin for the primary preven ...... women: a cost-utility analysis
@en
Aspirin for the primary preven ...... women: a cost-utility analysis
@nl
P2093
P3181
P1476
Aspirin for the primary preven ...... women: a cost-utility analysis
@en
P2093
Jeffrey A Tice
Mark J Pletcher
Stephanie Earnshaw
P3181
P356
10.1001/ARCHINTE.167.3.290
P407
P577
2007-02-12T00:00:00Z